Post-menopause is the period of life where a deep decline occurs in circulating estrogen levels, inducing the appearance of psycho and somatic symptoms. The classification to understand the chronology of reproductive aging in women (known as STRAW) determines the clinical and endocrine changes contemplating menstrual cycles, symptoms, measurements of FSH, LH, inhibin B, anti-Mullerian hormone , and follicular account. The diagnosis of menopause is established by the absence of menstruation for 12 months or more. The most frequent clinical manifestations of the climacteric syndrome transition to menopause are menstrual disorders, vasomotor symptoms (flushes and/or sweats) and genitourinary manifestations. The assessment of women in the peri- or postmenopause aims to develop: cervicovaginal cytology , lipid profile , serum glucose, basal Mammography at least a year before, pelvic ultrasound, urinalysis, serum TSH, Densitometry in patients older than 60 years if there is no recourse can be applied and FRAX. Drug therapy for the treatment of disorders of the transition to menopause or menopause is divided into: hormone therapy (HT) based estrogens and progestin hormone not being the most recommended the serotonin reuptake inhibitors and norepinephrine, clonidine, gabapentin or veralipride.

Download full-text PDF

Source

Publication Analysis

Top Keywords

transition menopause
8
[clinical practice
4
practice guideline
4
guideline diagnosis
4
diagnosis treatment
4
treatment postmenopausal
4
postmenopausal perinemopausia]
4
perinemopausia] post-menopause
4
post-menopause period
4
period life
4

Similar Publications

The transition to menopause is associated with disappearance of menstrual cycle symptoms and emergence of vasomotor symptoms. Although menopausal women report a variety of additional symptoms, it remains unclear which emerge prior to menopause, which occur in predictable clusters, how clusters change across the menopausal transition, or if distinct phenotypes are present within each life stage. We present an analysis of symptoms in premenopausal to menopausal women using the MenoLife app, which includes 4789 individuals (23% premenopausal, 29% perimenopausal, 48% menopausal) and 147,501 symptom logs (19% premenopausal, 39% perimenopausal, 42% menopausal).

View Article and Find Full Text PDF

Basic Science and Pathogenesis.

Alzheimers Dement

December 2024

University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.

Background: Estrogens, such as 17β-estradiol, are the primary female sex hormones predominantly synthesized by mature ovarian follicular cells. The natural exhaustion of ovarian follicular cells during menopause causes a rapid decline in endogenous estrogen levels. This decline in estrogen levels is associated with an increase in chronic, age-related pathologies, including inflammation in the brain.

View Article and Find Full Text PDF

Background: Estrogen is a master regulator of the bioenergetic system in the female brain, exerting broad control over metabolic processes from glucose transport to glycolysis, mitochondrial respiration, and ATP generation. The loss of estrogen during the perimenopausal transition is associated with decline in brain glucose metabolism and mitochondrial function which can contribute to the two-fold greater lifetime risk of Alzheimer's disease in postmenopausal women. While both ERα and ERβ have been reported to mediate E2 regulation of brain bioenergetic function, their cell-type specific contribution to bioenergetic homeostasis has yet to be elucidated.

View Article and Find Full Text PDF

Background: Menopause is a time of accelerated loss of physical function, illustrated by challenges to mobility, speed, strength, and performance of activities of daily living. Physical function is associated with cognitive function, but there are limited data exploring this association among older women. In a cohort of older adult women, we hypothesize better performance on measures of physical function will be associated with better cognitive performance.

View Article and Find Full Text PDF

Background: Women are more likely to experience sleep problems than men, especially during and after menopausal transition. Sleep disturbances are related to memory decline and the development of Alzheimer's disease (AD), which is also more common among women. While research on habitual sleep patterns in aging has largely focused on mean sleep outcomes across nights, few studies have examined the potentially harmful effects of night-to-night variability in sleep quality on AD biomarkers and memory function.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!